skip to main content
Idioma:
Primo Search
Clear Search Box
Search in: Busca Geral
Busca Avançada
Busca por Índices

Evaluating the cost utility of estradiol plus dydrogesterone for the treatment of menopausal women in China

Tamlyn Anne, Rautenberg ; Downes, Martin ; Simoncini, Tommaso ; Yu, Qi ; Ren, Mulan ; Wang, Yaping ; Graziano, Custodio Marcelo ; Kim, Kyoo

Journal of medical economics, 2024-12, Vol.27 (1), p.16-26 [Periódico revisado por pares]

England

Texto completo disponível

Citações Citado por
  • Título:
    Evaluating the cost utility of estradiol plus dydrogesterone for the treatment of menopausal women in China
  • Autor: Tamlyn Anne, Rautenberg ; Downes, Martin ; Simoncini, Tommaso ; Yu, Qi ; Ren, Mulan ; Wang, Yaping ; Graziano, Custodio Marcelo ; Kim, Kyoo
  • Assuntos: China ; Cost-Benefit Analysis ; Dydrogesterone - therapeutic use ; Economics, Pharmaceutical ; Estradiol - therapeutic use ; Female ; Hormone Replacement Therapy ; Humans ; Menopause ; Middle Aged ; Quality-Adjusted Life Years
  • É parte de: Journal of medical economics, 2024-12, Vol.27 (1), p.16-26
  • Notas: ObjectType-Article-1
    SourceType-Scholarly Journals-1
    ObjectType-Feature-2
    content type line 23
  • Descrição: Evaluate the cost utility of menopausal hormone therapy for women in China. A bespoke Markov cost utility model was developed to evaluate a cohort of symptomatic perimenopausal women (>45 years) with intact uterus in China in accordance with China's Pharmacoeconomic guideline. Short (5-year) and long (10-year) treatment durations were evaluated over a lifetime model time horizon with 12-month cycle duration. Societal and healthcare payer perspectives were evaluated in the context of a primary care provider/prescriber, outpatient setting with inpatient care for patients with chronic conditions. Disease risk and mortality parameters were derived from focused literature searches, and China Diagnosis-related Group cost data was included. Comprehensive scenario, univariate and probabilistic sensitivity analysis were undertaken along with independent validation. This is the first model to include MHT-related disease risks. According to base case results, the total cost for MHT was 22,516$ (150,106¥) and total quality adjusted life years 12.32 versus total cost of no MHT 30,824$ (205,495¥) and total quality adjusted life years 11.16 resulting in a dominant incremental cost effectiveness ratio of -7,184$ (-47,898¥) per QALY. Results hold true over a range of univariate deterministic sensitivity and scenario analyses. Probabilistic analysis showed a 91% probability of being cost effective at a willingness to pay threshold of three times Gross Domestic Product per capita in China. Contingent on the structure and assumptions of the model, combination of estradiol plus dydrogesterone MHT is potentially cost saving in symptomatic women over the age of 45 years in China.
  • Editor: England
  • Idioma: Inglês
Links
Voltar para lista de resultados
Ir para página anteriorAnterior Resultado  2 AvançarIr para próxima página

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.